Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- IVA
- Price
- 7.06
- Stock movement up
- +0.48 (7.29%)
- Company name
- Inventiva Sa
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 1.03B
- Ent value
- 1.10B
- Price/Sales
- 75.45
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 22.50%
- 1 year return (CAGR)
- 225.35%
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-01-22
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
IVA does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 75.45 |
| Price to Book | - |
| EV to Sales | 80.27 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 145.89M |
| EPS (TTM) | -3.31 |
| FCF per share (TTM) | -0.84 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 13.65M |
| Gross profit (TTM) | 11.95M |
| Operating income (TTM) | -154.36M |
| Net income (TTM) | -360.09M |
| EPS (TTM) | -3.31 |
| EPS (1y forward) | -1.71 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 87.52% |
| Operating margin (TTM) | -1130.68% |
| Profit margin (TTM) | -2637.66% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 122.08M |
| Net receivables | 22.79M |
| Total current assets | 172.37M |
| Goodwill | 0.00 |
| Intangible assets | 85.00K |
| Property, plant and equipment | 20.80M |
| Total assets | 178.52M |
| Accounts payable | 34.70M |
| Short/Current long term debt | 57.13M |
| Total current liabilities | 58.46M |
| Total liabilities | 187.87M |
| Shareholder's equity | -9.35M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -139.82M |
| Capital expenditures (TTM) | 390.00K |
| Free cash flow (TTM) | -91.61M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | -201.71% |
| Return on Invested Capital | -753.59% |
| Cash Return on Invested Capital | -191.73% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 6.61 |
| Daily high | 7.19 |
| Daily low | 6.60 |
| Daily Volume | 805K |
| All-time high | 19.00 |
| 1y analyst estimate | 15.88 |
| Beta | 0.78 |
| EPS (TTM) | -3.31 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 1 Apr 2026 |
Downside potential
Loading...
Downside potential data
| IVA | S&P500 | |
| Current price drop from All-time high | -62.84% | -0.89% |
| Highest price drop | -91.32% | -19.00% |
| Date of highest drop | 9 Oct 2024 | 8 Apr 2025 |
| Avg drop from high | -80.89% | -2.49% |
| Avg time to new high | - | 6 days |
| Max time to new high | 322 days | 89 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
1.03B
Marketcap category
Small-cap
Description
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. It also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. The company was incorporated in 2011 and is headquartered in Daix, France.
Employees
84
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page